Clinical Trial Update: A Retrospective Analysis of Cerefolin NAC® in Cognitively Impaired Patients

View source ↗

Summary

This document reports on a retrospective analysis of Cerefolin NAC in cognitively impaired patients. The focus is on individuals with mild cognitive impairment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment

Drugs mentioned

• Cerefolin NAC

Snippet

Sponsor: Pamlab, Inc. | Conditions: Mild Cognitive Impairment | Status: UNKNOWN